StockData
Immunovant, Inc. logo

Immunovant, Inc. (IMVT) income statement

IMVTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends March 31
Số liệu tài chính tới Q1 năm tài chính 2027, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 6/30
$33.17−0.04 (-0.12%)

Close on Nov 18, 2026Market cap $6.85BP/E –Yield –

Immunovant, Inc. income statement

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin
–
Operating margin
–
Net margin
–
Return on equity, FY2026
-64.8%

Financial strength

Current ratio
7.27
Debt to equity
–
Debt to assets
–
Cash to current liabilities
681.3%

Valuation

P/E ratio
–
Price to sales
–
Price to book
9.32
Dividend yield
–

See a number that looks wrong?